Fig. 5From: Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)Deleterious somatic mutations in 89 tumor samples. Tumors with available mutation data are grouped by radiological response along the x-axis, also showing clinicopathological characteristics for each tumor on the x-axis, the 91 genes of BreastCurie panel are enriched to 10 signaling on the y-axis. The somatic mutations of each tumor are indicated by colored boxes; red boxes indicate pathogenic variants, and blue boxes indicate unknown pathogenic variantsBack to article page